← Back to Search

#HerHeart tool for Cardiovascular Disease

N/A

Waitlist Available

Led By Holly Gooding, MD

Research Sponsored by Emory University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 3 month post-enrollment

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to test the #HerHeart web tool, which helps young women aged 13-21 understand their heart disease risk and adopt healthier habits. The tool provides information and tips to encourage a heart-healthy lifestyle.

Eligible Conditions

Cardiovascular Disease

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 3 month post-enrollment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 3 month post-enrollment

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3 month post-enrollment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

#HerHEART Risk Score in AYA From Baseline

Alcohol Consumption

Cereal Fiber

+7 more

Secondary study objectives

BMI From Baseline

Diastolic Blood Pressure (BP) From Baseline

Systolic Blood Pressure (BP) From Baseline

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: AYA participantsExperimental Treatment1 Intervention

AYA participants will complete a brief initial survey consisting of demographic information and the Visual Analog Scale (VAS) and the #HerHeart tool in clinic. AYA participants will the rate the usability of the #HerHeart tool using the Website Analysis and Measurement Inventory (WAMMI), the likelihood they would recommend the app to their friends, and the likelihood of behavior change. AYA participants will then be offered the opportunity to continue into the 3-month intervention phase.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

#HerHeart tool

2022

N/A

~60

Do I qualify?Apply below to find out